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Abstract
Background: Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and
overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel
treatment in phase III studies. These oral agents target androgen and androgen receptor signaling and are thought
to be less toxic than chemotherapy. Cross-resistance to these agents was recently reported because of their similar
mechanism of action, and it is important to assess which agent is more effective to use initially for CRPC.
Methods/design: The present study is a phase III, investigator-initiated, multicenter, head-to-head, randomized
controlled trial investigating enzalutamide vs. abiraterone as a first-line treatment for CRPC patients. Patients will
be randomly assigned to an enzalutamide or an abiraterone treatment group. The primary endpoint is the time
to prostate-specific antigen progression. The target sample size is set at 100 patients per group (total, 200 patients). The
study duration is 5 years, and the duration for recruitment is 2 years and 6 months.
Discussion: Thus far, there have been no prospective head-to-head studies comparing enzalutamide and abiraterone.
This ENABLE study will clarify which agent should be prioritized for CRPC patients and enable clinicians to decide the
appropriate treatment before chemotherapy.
Trial registration: University hospital Medical Information Network (UMIN) Center identifier UMIN000015529.
Registrated 11/1/2014.
Keywords: Androgen-deprivation therapy, Hormone therapy, Endocrine therapy, Castration-resistant prostate cancer,
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Background
Prostate cancer is the most common malignancy and the
second leading cause of death because of cancer in
males in the United States [1]. Moreover, the number of
prostate cancer patients in Japan has been increasing
continuously [2]. Because androgen and androgen receptor
signaling promotes prostate cancer progression, the stand-
ard treatment for patients with advanced prostate cancer
employs androgen-deprivation therapy (ADT) [3, 4]. How-
ever, prostate cancer often progresses to castration-resistant
prostate cancer (CRPC), a status that has acquired resist-
ance to ADTafter several years of treatment [5]. Both enza-
lutamide and abiraterone have demonstrated improved
radiographic progression-free survival (rPFS) and overall
survival (OS) compared with that with placebo controls
before docetaxel treatment [6, 7]. These oral agents target
androgen and androgen receptor signaling and are thought
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to be less toxic than chemotherapy (e.g., docetaxel and
cabazitaxel). A cross-resistance to these agents was recently
reported because of a similar anti-tumor mechanism, and it
is important to determine which agent is more effective to
use initially for CRPC patients [8, 9]. The benefit of enzalu-
tamide was shown with respect to the time taken for
prostate-specific antigen (PSA) progression (hazard ratio,
0.17), and a rate of decline of at least 50% in PSA (78% vs.
3%, P < 0.001) [6]. The median time to PSA progression
(TTPP) was 11.1 and 5.6 months in the abiraterone and
control group, respectively, with a 51% reduction in risk
(hazard ratio, 0.49, P < 0.001) [10]. In this phase III multi-
center randomized controlled trial (RCT), TTPP is set as a
primary endpoint, and a head-to-head comparison between
enzalutamide and abiraterone as a first-line endocrine ther-
apy for CRPC is performed.
Methods/design
Aim of the study
To evaluate the efficacy of enzalutamide vs. abirater-
one in the setting of a first-line treatment for CRPC
patients.
Study design
The present study is a phase III, investigator-initiated,
multicenter, RCT involving a head-to-head comparison
of enzalutamide vs. abiraterone for CRPC patients before
chemotherapy. Patients will be randomly assigned to an
enzalutamide or abiraterone treatment group as shown
in Fig. 1.
Additional measures
A validated health-related-quality-of-life questionnaire,
FACT-G ver4, which has been translated into Japanese,
will be administered before treatment, after the first
month, and every three months after the beginning of
treatment to comprehensively evaluate the various aspects
of physical and psychosocial well-being.
Eligibility criteria: Inclusion criteria
Patients must:
1. Have pathologically or cytologically confirmed CRPC,
defined as total testosterone levels <50 ng/dL and two
consecutive PSA elevations with a week interval,
where PSA used for judgment is at least 2 ng/mL
higher than nadir.
2. Have had no previous cytotoxic intravenous
systemic chemotherapy.
3. Are ≥20 years when providing written informed
consent.
4. Have a performance status (PS) of 0–2 according to
the Eastern Cooperative Oncology Group.
5. Have appropriate hepatic and renal functionality as
demonstrated in laboratory tests within four weeks prior
to registration: total bilirubin level ≤ 1.5 × upper limit of
normal (ULN); aspartate transaminase ≤2.5 × ULN (≤
5.0 × ULN in patients with liver metastasis); alanine
transaminase ≤2.5 × ULN (≤ 5.0 × ULN in patients with
liver metastasis); and serum creatinine ≤2.0 × ULN.
Neither ascites nor hepatic encephalopathy are present.
6. Have a life expectancy > three months.
Fig. 1 UMIN000015529
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Eligibility criteria: Exclusion criteria
Patients are ineligible if they:
1. Have an allergy to enzalutamide, abiraterone, or
prednisolone.
2. Have a desire to have children.
3. Are considered by a principal or clinical investigator
to be inappropriate for participation in the present
study for any other reason.
Informed consent: Ethics approval
This study is conducted in accordance with the Declar-
ation of Helsinki 1975, as revised in 2013. All treatments
and examinations for prostate cancer are undertaken
following written informed consent before registrations.
The ENABLE study for prostate cancer (ENABLE study)
received approval from the institutional ethics committees
of the participating institutions.
Methods of recruitment and random allocation
Recruitment began in November 2014 and is planned
for completion by April 2017. Eligible patients are ran-
domly assigned to one of two treatment groups through
the data center at the Innovative Clinical Research Center,
Kanazawa University (iCREK). Randomization is centrally
performed by Waritsukekun (Mebix, Tokyo, Japan) using
a minimization method to obtain adequate between-group
balance for age category (<70 or ≥70), PS (0–1/2), status
of metastasis (none, bone alone, or other than bone), and
participating institution.
Administration of enzalutamide and abiraterone
Enzalutamide at a dose of 160 mg/d (four 40 mg tablets
once per day), is orally administered to patients who are
assigned to the enzalutamide group. Abiraterone at a
dose of 1000 mg/d (four tablets of 250 mg once per
day), and 5 mg prednisolone twice per day, are orally
administered to patients who are assigned to the abira-
terone group. If a principal or clinical investigator con-
siders the basic doses inappropriate for any reason,
reduction of the doses is permitted. A history of any
other treatments for which efficacy has not been shown
in RCT to date is permitted, with the exception of cyto-
toxic intravenous chemotherapies. The administration of
enzalutamide or abiraterone + prednisolone is termi-
nated when: 1) PSA progression is confirmed; 2) the
patient dies; or 3) severe adverse events occur. Luteinizing
hormone-releasing hormone agonist (or antagonist) is
continued throughout the study. Zoledronic acid and
denosumab are permitted for patients with bone metasta-
sis. Any sequential treatments are permitted after the con-
firmation of PSA progression in both groups.
Data collection
All patients providing written informed consent to
participate in the study are asked to complete a medical
history. Clinical data that will be obtained in the ENABLE
study include the Eastern Cooperative Oncology Group PS,
physical examination findings (i.e., height, body weight,
body temperature, and blood pressure), hematological test
results (e.g., white blood cell, red blood cell, hemoglobin,
hematocrit, and platelet counts), blood biochemical test
results (e.g., total testosterone, alkaline phosphatase, bone
alkaline phosphatase, total bilirubin, creatinine, liver
enzymes, and electrolytes), urine test results, chest X-
ray imaging, lung to pelvic computed tomography (CT)
or magnetic resonance imaging (MRI), brain CT or
MRI, bone scintigraphy with or without a bone scan
index, electrocardiography, and the quality-of-life ques-
tionnaire, FACT-G ver4. The chest X-ray and brain CT
are performed at the time of study registration. Other
examinations are performed every month from the date
of commencement to the sixth month, and every three
months after the sixth month until the study is com-
pleted (Fig. 2). However, if a principal or clinical inves-
tigator considers these examinations to be necessary,
they can be performed at any time.
Definition of endpoints
The primary endpoint is TTPP, defined on the basis of
prostate cancer working group 2 (PCWG2) criteria [5]
as described briefly below. For patients in whom PSA
declines at week 13, PSA progression date is defined as
the date that a ≥ 25% increase and an absolute increase
of ≥2 ng/mL above the nadir is documented. This
increase was confirmed by a second consecutive value
obtained at least three weeks later. For patients without
a PSA decline at week 13, PSA progression date was de-
fined as the date that a ≥ 25% increase and an absolute
increase of ≥2 ng/mL above the baseline is documented.
This is confirmed by a second consecutive value, at least
three weeks later. For all patients, TTPP was defined as
the time from randomization to first confirmed PSA
progression.
Eight secondary endpoints are set in ENABLE study as
follows:
1. OS, defined as the time from randomization to
death from any cause.
2. rPFS based on the Response Evaluation Criteria in
Solid Tumors (RECIST) criteria for soft-tissue lesions
examined with CT or MRI and PCWG2 criteria for
bone metastasis examined with bone scintigraphy.
3. Time to the commencement of cytotoxic
chemotherapy (e.g., docetaxel and cabazitaxel).
4. Time to stage progression in PS.
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5. Time to the commencement of opioid analgesics for
cancer pain.
6. PSA response rate (≥50% decline in PSA level from
baseline).
7. Safety according to the frequency and grade using
Common Terminology Criteria for Adverse Events
(CTCAE), Version 4.0 (http://evs.nci.nih.gov/ftp1/
CTCAE/About.html).
8. Health-related quality-of-life using FACT-G ver4.
Three exploratory endpoints are set in ENABLE study:
1. The type of secondary treatment.
2. OS from the randomization of the ENABLE study as
a sequential therapy, in case the secondary treatment
is docetaxel.
3. TTPP, rPFS, and PSA response rate after the
commencement of secondary treatment.
Planned statistical analyses
TTPP of the treatment and control group in the studies
on enzalutamide and abiraterone before chemotherapy
was 11.2 vs. 2.8 months and 11.1 vs. 5.6 months,
respectively [6, 7, 10]. The addition of prednisolone is
required to compensate for the decrease in cortisol
levels due to abiraterone. Prednisolone has been reported
to have a moderate anti-tumor effect in prostate cancer
patients and to extend 2 months in TTPP [11]. As pred-
nisolone was administered to all patients in the abirater-
one study, TTPP of the abiraterone treatment group may
be reduced to 3.6 months. The inclusion of patients with
visceral metastasis might be a potential reason for this
difference between the control groups (2.8 and 3.6 months)
in the two studies. If the patient backgrounds of these
two studies are same, TTPP of the abiraterone treat-
ment group before chemotherapy is 11.2 × (2.8/
3.6) = 8.6 months. Using this calculated hypothetical
TTPP in abraterone group, TTPP in enzalutamide
group (11.2 months) is 2.6 months superior to TTPP
in abiraterone group (8.6 months). We calculated the
sample size from 5 years of the study duration and the
difference in TTPP between the enzalutamide and
abiraterone groups. The basic methods of statistical
analyzes were described in a previous study [12]. At
least, 91 patients in each group are required to detect
a significant difference between the enzalutamide and
abiraterone groups by a log-rank test with a signifi-
cance level of 0.05 and a power of 80%. Furthermore,
given the assumption that approximately 10% of ran-
domized patients will not be evaluable for various rea-
sons, the target sample size was set at 100 patients per
group (total 200 patients). Intention-to-treat analyses
will be performed, and survival curves will be esti-
mated using the Kaplan–Meier method. A log-rank
test will be used to test for differences in the survival
curves between the two groups of patients. The hazard
ratio will be estimated using the Cox proportional
hazard model. Moreover, the longitudinal changes in
the health-related-quality-of-life between time of diag-
nosis and during treatment will also be compared
between the two groups. All patients will be evaluated
for toxicity, and the incident proportion of grade 3 ad-
verse events will be compared between the groups by
a Fisher’s exact test. All tests will be two-sided, and a
P-value of 0.05 will be considered statistically signifi-
cant. The study will be completely analyzed two and a
half years after the last patient is recruited.
Patient enrollment and anticipated completion of
enrollment
Our current expectation is that the final patient will be
enrolled by April 2017, and the entire study will be com-
pleted by October 2019. Cumulative enrollment reached
40 cases as of February 2016.
Discussion
Docetaxel has been used as a first-line treatment for
CRPC after the proof of its efficacy in a randomized
phase III study in 2004 [6, 7]. Although the Japanese
government approved docetaxel for CRPC in 2008 and it
is often used clinically, it is a cytotoxic agent and can
be unsuitable for treating older patients and those with
Fig. 2 A follow-up schedule
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co-morbidities. There was no other treatment for which
efficacy was proven by a phase III study until 2010.
Cabazitaxel emerged as a second-line treatment for
CRPC for the first time in 2010 [13]. Subsequently, the
efficacies of four treatment lines, enzalutamide, abira-
terone, sipuleucel-T, and radium-223, were demon-
strated by phase III studies in consecutive publications
[6, 10, 14, 15]. There has been no head-to-head study
performed for these novel treatments for CRPC, which
complicates the CRPC treatment decisions taken by clini-
cians. Previously, prostate cancer in ADT-resistant patients
was referred to as hormone-refractory prostate cancer. It
was reported that prostate cancer cells take advantage of
the low levels of androgens after ADT, and androgens are
even synthesized in the prostate cancer cells. Therefore, the
term “CRPC” is currently used following confirmation of
low total testosterone levels, typically defined as <50 ng/dL
[5]. Abiraterone inhibits CYP17A1 (both 17a–hydroxylase
and 17,20-lyase) in androgen biosynthesis, whereas enzalu-
tamide binds to the androgen receptor with a greater
relative affinity than conventional anti-androgen agents, re-
duces the efficiency of its nuclear translocation, and impairs
both DNA binding to androgen response elements and
recruitment of coactivators [16, 17]. Therefore, it was con-
sidered to be of great value to compare these two orally ad-
ministered hormonal treatments with low toxicity.
TTPP was set as a primary endpoint in the ENABLE
study, which differed from previous studies that used
OS and rPFS as the primary endpoints [6, 7, 10]. The
ENABLE study was planned to investigate patients before
chemotherapy, and the OS may substantially depend on
subsequent treatments. Moreover, conventional hormonal
manipulations (e.g., ethinylestradiol, estramustine phos-
phate, and dexamethasone) can also have an anti-tumor
effect, and may extend the OS if used after the ENABLE
study [18–20]. Although it may be universal for studies of
cancer to use rPFS with RECIST, it may not be applied to
an advanced prostate cancer study due to its extremely
high frequency of bone metastasis [21]. If rPFS is used as
a primary endpoint, the quantitation of bone metastasis is
necessary to correctly assess the disease status [22]. Inter-
estingly, 43% of cases of cancer progression could be
detected by PSA but not radiographic progression. Never-
theless, only 13% of cases of cancer progression could be
detected by radiographic progression alone [6]. Although
PSA has potential limitations as reported previously, the
PSA assay is extremely easy to perform, is relatively inex-
pensive, and less invasive because PSA consists of secreted
proteins present in the blood [23–25].
Recently, although a prospective phase II study com-
paring enzalutamide and abiraterone (NCT02125357)
showed no difference in time to PSA progression [26],
this is a cross-over study of abiraterone vs enzalutamide
and still ongoing. There have been no prospective head-
to-head phase III studies comparing enzalutamide and
abiraterone conducted to date. The ENABLE study is
the first study of its kind, will clarify which agent should
have priority for CRPC patients, and will enable clini-
cians to decide the most appropriate treatment before
chemotherapy.
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